SCYX - SCYNEXIS, Inc.

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
0.8 0.02 (2.73%)	---	0.0 (0.0%)	0.0 (0.06%)	0.1 (13.05%)	-0.06 (-6.76%)	-0.01 (-1.23%)	-0.01 (-1.23%)

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.11
Diluted EPS:: -0.11
Basic P/E:: -7.4345
Diluted P/E:: -7.4345
RSI(14) 1m:: 100.0
VWAP:: 0.82
RVol:: 3.0768

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	0.86 +0.01 (+1.04%)	Oct 15 16:28
1m	Price decrease 1m	0.84 -0.01 (-1.56%)	Oct 15 12:13
1m	Price increase 1m	0.85 +0.01 (+1.18%)	Oct 15 12:08
1m	Price increase 1m	0.88 +0.02 (+2.55%)	Oct 15 10:58
1m	Price increase 1m	0.88 +0.02 (+2.55%)	Oct 15 10:58